Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma:Comparison Between the Model for End-stage Liver Disease (MELD), MELD-sodium, and Five Cancer Staging Systems

Journal of Clinical Gastroenterology

Volumn 43, Issue 8, 2009, Pages 773-781

  Huo, Teh Ia ^a   Hsia, Cheng Yuan ^a   Huang, Yi Hsiang ^b   Lin, Han Chieh ^b   Lee, Pui Ching ^c   Lui, Wing Yiu ^c   Chiang, Jen Huei ^c   Chiou, Yi You ^c   Loong, Che Chuan ^c   Lee, Shou Dong ^c  

^a Departments of Medicine   (Taiwan)

^b Institute of Pharmacology   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BCLC; CLIP; Hepatocellular carcinoma; JIS; MELD; MELD Na; TNM; Tokyo score

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; METHODOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; SURVIVAL; SURVIVAL RATE;

AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 77549086572     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31818dd962     Document Type: Article

References (41)

1. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
3. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-715.
4. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419-425.
5. Huo TI, Lee SD, Wu JC. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol. 2004;40:1041-1042.
6. Huo TI, Huang YH, Lee SD, et al. Is there an ideal prognostic model for hepatocellular carcinoma? Gut. 2005;54:1348.
7. The Cancer of the Liver Italian Program (CLIP) investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840-845.
8. Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology. 2004;39:550-551.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
10. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405.
11. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
12. Freeman RB, Wiesner RH, Roberts JP, et al. Improving liver allocation: MELD and PELD. Am J Transplant. 2004;4(suppl 9):114-131.
13. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transplant. 2001;7:567-780.
14. Olthoff KM, Brown RS Jr, Delmonico FL, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. Liver Transpl. 2004;10(10 suppl 2):A6-A22.
15. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40:897-903.
16. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494-500.
17. Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52:134-139.
18. Huo TI, Lee PC, Huang YH, et al. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol. 2006;40:543-550.
19. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652-1660.
20. Ando E, Kuromatsu R, Tanaka M, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol. 2006;40:942-948.
21. Davila JA, Weston A, Smalley W, et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41:777-782.
22. Huo Tİ, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101:975-982.
23. Huo Tİ, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing loco-regional therapy. Cancer. 2006;107:141-148.
24. Huo TI, Wu JC, Lui WY, et al. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and non-surgical treatment. Am J Gastroenterol. 2004;99:1479-1487.
25. Huo TI, Lin HC, Hsia CY, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102:1920-1930.
26. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-430.
27. Lei HJ, Chau GY, Lui WY, et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg. 2006;203:426-435.
28. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
29. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
30. Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12:1049-1061.
31. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40:124-131.
32. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723-731.
33. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005;100:1764-1771.
34. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
35. Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132:1261-1269.
36. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:25-34.
37. Allgaier HP, Deibert P, Olschewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. Int J Cancer. 1998;79:601-605.
38. Pompili M, Rapaccini GL, de Luca F, et al. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer. 1997;79:1501-1508.
39. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760-1769.
40. Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35(5 suppl 2):S130-S137.
41. Chan HL, Chim AM, Lau JT, et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol. 2006;101:1516-1523.